A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma

Landgren, Ola; Björkholm, Magnus; Konradsen, Helle Bossen; Soderqvist, M; Nilsson, Bo; Gustavsson, Anita; Axdorph, Ulla; Kalin, Mats; Grimfors, Gunnar

doi:10.1111/j.1365-2796.2004.01312.x

Cited by 56 publications

(34 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 The finding that antibody responses are maintained after 2 or 3 doses is consistent with a study that evaluated the immunogenicity of multiple pneumococcal polysaccharide doses in splenectomized patients aged 6 to 81 y, the majority of whom had Hodgkin's lymphoma. 28 These participants had statistically significant immune responses 1 mo after first, second or third doses. In addition, 1 y after each dose, antibody levels were below 1-mo peaks but higher than prevaccination baseline levels.…”

Section: Methodsmentioning

confidence: 92%

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

Musher¹,

Manoff²,

McFetridge³

et al. 2011

Human Vaccines

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 92%

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

Musher¹,

Manoff²,

McFetridge³

et al. 2011

Human Vaccines

View full text Add to dashboard Cite

show abstract

“…2 This therapeutic success has unfortunately been darkened by elevated risks of secondary primary cancers, cardiovascular disease (CVD), cerebrovascular disease, and infections in longterm HL survivors. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] CVD has been reported to be the most important cause of excess mortality after HL and second malignancies. [10][11][13][14] During the last 2-3 decades, treatment strategies have been and are being adapted based on increased knowledge of treatment-related morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009

Sjøberg

Halthur

Kristinsson

et al. 2012

Blood

View full text Add to dashboard Cite

In recent decades, attention has focused on reducing long-term, treatment-related morbidity and mortality in Hodgkin lymphoma (HL). In the present study, we looked for trends in relative survival for all patients diagnosed with HL in Sweden from 1973-2009 (N ‫؍‬ 6949; 3985 men and 2964 women; median age, 45 years) and followed up for death until the end of 2010. Patients were categorized into 6 age groups and 5 calendar periods (1973-1979, 1980-1986, 1987-1994, 1994-2000, and 2001-2009 IntroductionOver the past 40 years, major advances have been made in the management of patients with Hodgkin lymphoma (HL). These include the introduction of more accurate radiotherapy, effective multiagent chemotherapy, immunotherapy, improved staging procedures, and important developments in supportive measures for myelosuppression and infectious and other complications. 1 Therefore, HL has gone from being an invariably fatal disorder to one of the few malignancies that are now highly curable. This is particularly true for patients with early-stage disease, but today disease control rates also exceed 70% in patients presenting with high-risk features. 2 This therapeutic success has unfortunately been darkened by elevated risks of secondary primary cancers, cardiovascular disease (CVD), cerebrovascular disease, and infections in longterm HL survivors. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] CVD has been reported to be the most important cause of excess mortality after HL and second malignancies. [10][11][13][14] During the last 2-3 decades, treatment strategies have been and are being adapted based on increased knowledge of treatment-related morbidity and mortality. Awaiting novel and less toxic targeted therapies of HL, the largest potential for improving survival and healthrelated quality of life in long-term survivors 17 is by reducing the excess morbidity and mortality from causes other than HL. To evaluate progress in long-term outcome, we studied patient survival among all 6949 HL patients diagnosed in Sweden between 1973 and 2009 and followed up for death to the end of 2010. Our aim was to assess trends in patient survival and long-term excess mortality in the entire population during this 37-year period starting when curative treatment principles were well-established. Methods Central registers and patientsInformation regarding patients diagnosed with a malignant disorder in Sweden is reported to a population-based nationwide Swedish Cancer Register that was established in 1958. The register contains information on diagnosis, sex, date of birth, date of diagnosis, and the hospital where the diagnosis was made, 18-19 but does not contain detailed clinical information such as symptoms, routine laboratory tests, treatment, or comorbidities.In Sweden, every physician and pathologist/cytologist is obliged by law to report each occurrence of cancer to the registry. All deaths are recorded in the nationwide causes of death register. Each person in Sweden is given a unique national registration number used to index a...

show abstract

“…In addition, 5% of patients who were given vaccination after splenectomy developed OPSI. For elective splenectomy, the vaccine should be given at least 2 week before surgery [19]. Vaccines available for the most common organisms include the 23-valent pneumococcal polysaccharide vaccine, the Hemophilus influenza type B vaccine and the Meningococcal vaccine [20].…”

Section: Prevention Of Opsimentioning

confidence: 99%

Overwhelming Postsplenectomy Infection for Splenectomized HCV Patients

Hashimoto¹

2015

OALib

View full text Add to dashboard Cite

Pegylated-interferon (IFN) plus ribavirin remains the most effective therapeutic regimen for patients with chronic hepatitis C interferon. Thrombocytopenia is a common side effect of this treatment, often leading to discontinuation of a potentially curative therapy. Splenectomy was a clinically effective treatment for hepatitis C virus-associated thrombocytopenia. Splenectomy in patients with hepatitis C cirrhosis is now safer prelude to antiviral treatment. Overwhelming post splenectomy infection (OPSI) syndrome is a rare condition, but is associated with high mortality. However, recognition and clinical management of OPSI is not well established. We reviewed the literature characterizing the clinicopathological features of OPSI and assessed the most effective and feasible administration of the condition. Prevention strategies such as vaccination and education are also potentially important parts of the strategy for splenectomized HCV patients.

show abstract

A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma

Cited by 56 publications

References 47 publications

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009

Overwhelming Postsplenectomy Infection for Splenectomized HCV Patients

Contact Info

Product

Resources

About